California Nanotechnologies Corp.

As of May 31, 2026, California Nanotechnologies Corp. carries a market capitalization of 11.70M, placing it among publicly traded companies globally. Its enterprise value stands at 12.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

California Nanotechnologies Corp.'s next confirmed earnings release is scheduled for November 2, 2026.

As of May 31, 2026, California Nanotechnologies Corp. has 46.76M shares outstanding.

These figures are as of May 31, 2026. The price-to-sales ratio is 2.94, and the price-to-book ratio stands at 3.62.

These figures are as of May 31, 2026. The EV/Sales ratio of 3.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.75M versus a market cap of 11.70M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, California Nanotechnologies Corp. maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.38, indicating elevated leverage, while an interest coverage ratio of -12.08 demonstrates limited ability to service its debt obligations.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp. posted a negative return on equity (ROE) of -86.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -42.61, reflecting losses generated across the asset base. The company generates approximately 201,831.59 in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp. recorded 5,638.58 in income tax expense. The company reported a pretax loss of -2.77M and -2.78M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, California Nanotechnologies Corp.'s stock has declined approximately 1.27% over the past 52 weeks. The 50-day moving average sits at 0.32, while the 200-day moving average is 0.66.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp. generated 4.04M in revenue and converted that into -2.78M in net income, yielding earnings per share of -0.06. EBITDA reached -1.98M, while operating income came in at -2.83M.

As of May 31, 2026, California Nanotechnologies Corp. holds 379,393.02 in cash and equivalents against 1.43M in total debt, resulting in a net debt position of -379,393.02. Total book value stands at 3.23M, with working capital of 486,301.18 providing operational flexibility.

California Nanotechnologies Corp. produced -843,270.92 in operating cash flow over the twelve months ended May 31, 2026. After subtracting -82,333.18 in capital expenditures, free cash flow totaled -925,604.09 - equivalent to -0.02 per share.

Over the twelve months ended May 31, 2026, California Nanotechnologies Corp. posted a gross margin of 48.95, reflecting its pricing power and cost economics. The operating margin of -69.99 and net profit margin of -68.83 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -7.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.51, meaning California Nanotechnologies Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of May 31, 2026, California Nanotechnologies Corp. has an Altman Z-Score of 0.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.